Stocktoria
Caribou Biosciences, Inc. CRBU
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-23
Caribou Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M |
| R&D expense | $109.4M | $130.2M | $112.1M | $82.2M | $52.3M |
| Operating income | -$148.3M | -$166.6M | -$116.1M | -$106.4M | -$67.0M |
| Interest expense | — | — | — | — | $8,000 |
| Income tax | -$550,000 | -$9,000 | $193,000 | $70,000 | $321,000 |
| Net income | -$148.1M | -$149.1M | -$102.1M | -$99.4M | -$66.9M |
| EPS (diluted) | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 |
| Operating cash flow | -$111.0M | -$138.2M | -$93.3M | -$91.0M | -$32.5M |
| Free cash flow | -$112.4M | -$143.1M | -$104.9M | -$97.4M | -$34.6M |
| Cash & equivalents | $12.4M | $16.3M | $51.2M | $58.3M | $240.4M |
| Total assets | $175.4M | $313.3M | $432.2M | $373.8M | $442.4M |
| Total liabilities | $53.2M | $60.4M | $63.8M | $72.9M | $54.5M |
| Shareholders' equity | $122.2M | $253.0M | $368.4M | $300.9M | $387.8M |
Source: SEC EDGAR filings · CIK 0001619856 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.